Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Status Withdrawn

Clinical Trial Summary

This is an open label dose escalation study to find the maximum tolerated dose (MTD) of PKI-179 in subjects with solid tumors. Part 1 of the study will be the dose estimation phase and will be open to subjects with all solid tumors. Part 2 will be the dose confirmation phase and will be open to subjects with breast, non small cell lung, ovarian, endometrial, or colorectal cancer or glioblastoma. All subjects will receive daily oral dosing of PKI-179. A continuous reassessment method (CRM) design will be used, which will take into account dose limiting toxicity (DLT) information from each dose level explored in order to determine the next dose level.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Malignant Solid Tumors

Clinical Trial Details

NCT number	NCT00997360
Study type	Interventional
Source	Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status	Withdrawn
Phase	Phase 1
Start date	February 2010
Completion date	February 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00728468` - A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients	Phase 1
Completed	`NCT00445458` - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer	Phase 1/Phase 2
Completed	`NCT00768469` - Study Evaluating Safety And Tolerability, Solid Tumor	Phase 1
Recruiting	`NCT04226066` - Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04908046` - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06464055` - A Study of GQ1010 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06231550` - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors	Phase 1
Not yet recruiting	`NCT05383703` - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor	Phase 1
Recruiting	`NCT05773937` - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT04328506` - Bioequivalency Study of CM082 Tablet in Healthy Volunteers	Phase 1
Recruiting	`NCT05886374` - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT00958724` - Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors	Phase 1
Not yet recruiting	`NCT05949775` - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors	N/A
Terminated	`NCT02045095` - A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors	Phase 1
Completed	`NCT00884845` - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT05277454` - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT	Phase 1
Active, not recruiting	`NCT03792958` - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT04126668` - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers	Phase 1
Recruiting	`NCT05338957` - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.	Phase 1/Phase 2
Recruiting	`NCT03047811` - The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors	N/A